Exclusive Research on Neuroscience Market 2020 by and Key Companies Analysis Doric Lenses Inc, GE Healthcare, Mightex Systems, Prizmatix, Noldus…

Europe Fall Detection System Market is estimated to reach USD 114.70 Million by 2025 from USD 83.59 Million in 2017, growing at a CAGR of 4.2% in the forecast period 2018 to 2025. The new market report contains data for historic years 2016, the base year of calculation is 2017 and the forecast period Data Bridge Market research released a new market study on Europe Fall Detection System Market with 100+ market data Tables, Pie Chart, Graphs & Figures spread through Pages and easy to understand detailed analysis. At present, the market is developing its presence. The data involved in this Europe Fall Detection System market report can be very necessary when it comes to dominating the market or making a mark in the market as a new emergent. Furthermore, it endows with historic data, present market trends, environment, technological innovation, upcoming technologies and the technical progress in the related industry. Europe Fall Detection System market research report forecasts the size of the Semiconductors and Electronic industry with information on key vendor revenues, development of the industry by upstream & downstream, industry progress, key companies, along with segment type & market application. This report analyses the Semiconductors and Electronic industry from top to bottom by considering myriad of aspects.

Available Exclusive Sample Copy of this Report @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=europe-fall-detection-system-market&DP

If you are involved in the Europe Fall Detection System industry or intend to be, then this study will provide you comprehensive outlook. Its vital you keep your market knowledge up to date segmented Europe Fall Detection System Market, By Product Type (Automatic Fall Detection System, Manual Fall Detection System), By Algorithm (Simple Threshold, Machine Learning), By Component (Accelerometers & Gyroscopes, Unimodal/Bimodal Sensors, Multimodal Sensors), By System (Wearable Systems {Watches, Clip-On, Necklace}, Non-Wearable Systems, In-Home Landline System, In-Home Cellular Systems), End-User (Home Care Settings, Hospitals and Senior Assisted Living Facilities, Lone Workers, Others), By Country (Germany, France, U.K., Spain, Italy, Russia, Netherlands, Turkey, Belgium, Switzerland, Rest of Europe) Industry Trends and Forecast to 2025

Top 10 Companies in the Europe Fall Detection System Market Research Report:

Koninklijke Philips N.V., Intel Corporation, VitalConnect, Blue Willow Systems, LifeCall, Williamson Corporation, Life Assure, Singapore Technologies Engineering Ltd, Semtech Corporation, Connect America, Tunstall, Bay Alarm Medical, MobileHelp, Mytrex, Inc., AlertOne Services, LLC and MariCare, among others.

Product definition-:The major factors driving the growth of this market are ability to assist in case of fall, growth in enhanced medical alert services, increased demand of wearable technology based fall detection system and growth in demand of smart phones. On the other hand, low acceptance of technology among elder population may hinder the growth of the market.

Europe Fall Detection System Market Country Level Analysis

The countries covered in Europe Fall Detection System market report are U.K., Germany, France, Netherlands, Russia, Belgium, Italy, Spain, Switzerland, Turkey and Rest of Europe.

Key Drivers:Europe Fall Detection System Market

Some of the key factors driving the market for Europe fall detection system are ability to assist in case of fall, growth in enhanced medical alert services. Increased demand of wearable technology based fall detection system and growth in demand of smart phones are the other factor which will drive the demand of Europe fall detection system market.

Strategic Key Insights Of The Europe Fall Detection System Report: Production Analysis Production of the Patient Handling Equipment is analyzed with respect to different regions, types and applications. Here, price analysis of various Europe Fall Detection System Market key players is also covered.

Sales and Revenue Analysis Both, sales and revenue are studied for the different regions of the Europe Fall Detection System Market. Another major aspect, price, which plays an important part in the revenue generation, is also assessed in this section for the various regions.

Supply and Consumption In continuation of sales, this section studies supply and consumption for the Europe Fall Detection System Market. This part also sheds light on the gap between supply and consumption. Import and export figures are also given in this part.

Competitors In this section, various Europe Fall Detection System industry leading players are studied with respect to their company profile, product portfolio, capacity, price, cost, and revenue.

Analytical Tools The Europe Fall Detection System Market report consists the precisely studied and evaluated information of the key players and their market scope using several analytical tools, including SWOT analysis, Porters five forces analysis, investment return analysis, and feasibility study. These tools have been used to efficiently study the growth of the major industry participants.

The 360-degree Europe Fall Detection System overview based on a and regional level. Market share, value, volume, and production capacity is analyzed on , regional and country level. And a complete and useful guide for new market aspirants

Facilitates decision making in view of noteworthy and gauging information also the drivers and limitations available of the market.

TOC points of Europe Fall Detection System Market Report:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe, MEA or Asia Pacific.

Table Of Contents Is Available [emailprotected] https://www.databridgemarketresearch.com/toc/?dbmr=europe-fall-detection-system-market&DP

Queries Related to the Europe Fall Detection System Market:

About Data Bridge Market Research:

An absolute way to forecast what future holds is to comprehend the trend today!

Data Bridge set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market. Data Bridge endeavors to provide appropriate solutions to the complex business challenges and initiates an effortless decision-making process.

Data Bridge adepts in creating satisfied clients who reckon upon our services and rely on our hard work with certitude. We are content with our glorious 99.9 % client satisfying rate.

Contact:

Data Bridge Market ResearchUS: +1 888 387 2818UK: +44 208 089 1725Hong Kong: +852 8192 7475Email:[emailprotected]

The rest is here:
Exclusive Research on Neuroscience Market 2020 by and Key Companies Analysis Doric Lenses Inc, GE Healthcare, Mightex Systems, Prizmatix, Noldus...

Brand Alchemy: A Conversation With Artist Of Science Spark Neuros Spencer Gerrol – Forbes

Data-led creativity has reached an inflection point. As a result, the era of art and commerce is giving way to a new age of art and science. We are amidst a data transformation revolution and the customer topography has never been more complex. Finding the right mix of algorithm and humanity is the Holy Grail or ultimate brand hack, no matter who you are, what youre marketing, or who you are selling to.

A Conversation with Artist of Science Spark Neuros Spencer Gerrol

A palpable need to formulate best-in-class brand alchemy is the new strategic imperative. This is the reason the past generation of artists of business I hailed in my book WE-Commerce, is quickly giving way to a new breed of executive that I am calling artists of science.

Consequently, Ive decided to launch a new Brand Alchemy Q+A series in parallel with my Ask the CMO column. Ive done this to get into the minds of this new species of leadership, as I believe they will ultimately emerge as the creative Darwinists defining the future of both business and brand.

For my latest conversation in this special series, I sat down with my friend Spencer Gerrol, CEO of Spark Neuro. Spencer is a visionary leading the charge on the new neuroscience revolution, and someone who intimately understands the elegantly symbiotic relationship creativity and science must have today. Following is a recap of our conversation:

Billee Howard: I would love to start with a very broad question, which is related to recent discussions around brands becoming too algorithmic. Now, there seems to be a course correction taking place and much discourse around how you marry humanity and science in the right way. What are your thoughts?

Spencer Gerrol: Its a great question. Lets start by reviewing the context behind how we got to this point through the history of brands working in the creative space and how that has evolved over time.

Rewind, and envision the days of Mad Men, the advertising world of the 1960s. Ads were created on gut instinct and dramatically pitching stories to brand executivesno data to speak of. Today, that sounds like blasphemy as brands have become hungry for data-driven decisions.

Next the pendulum swung in the other direction; data was king, and numbers made the decisionsbut creativity often suffered. When we see a pendulum swing, we need to look at the consequences.

The fact is that a huge part of any creative process is instinctual and that shouldnt go away. At Spark Neuro we measure emotion and one thing we emphasize is that emotion is the most powerful tool human beings have. Its not just how we process the stories we hear; it is also at the core of how people envision and create art. What we call instincts, your gut, is actually emotion doing its job to guide you.

When we fast-forward in time from Mad Men to todays data-driven companies, some natural tension arose. Many creatives pay lip service to data (and even rebel against it) and researchers have become a tool to push in the other direction.

I believe weve reached a pivotal point in finding the right balance to take us forward. You have to be data-driven, but you cant lose the sense of humanity when listening to the numbers. If we're looking at just who clicked on or watched what, that data is often devoid of understanding the core of human emotion. In order to study that emotional center, practical applications of neuroscience have made great strides.

Howard: I think that is a great place to pivot to my next question. I think it's ironic that people have been less afraid of AI because of its ability to be scientific and sort through data when it often lacked a tremendous amount of humanity, whereas people have been more afraid of neuroscience, which actually has humanity and empathy at its core. I would love you to explain how the use of neuroscience can actually bring more humanity to brands and help sharpen customer understanding.

Gerrol: The introduction of neuroscience into brand research starts with understanding the status quo of consumer research. When researchers started to introduce data, the tools at our disposal were rooted in self-report, that is, what people say. Surveys and focus groups do their best to tell us how people feel, but the methods are lacking. Group-think (everyone aligning or following a leader regardless of their true feelings), social desirability bias (people wanting to look good or not be judged and answering accordingly), and a host of other biases can steer us wrong even when we think the evidence is pointing us in the right direction.

Then there's the behavioral data; big data that tells you whos doing what. That's incredibly powerful, but by nature, big data tells you what people are doing, yet it doesn't tell you why they are doing it.

Companies can try to create models that predict those behaviors; however, at some point we need to make people feel a certain way to change or amplify behavior.

In order to be more creative, we need better science and a better way of integrating that science with the creative process. Neuroscience allows us to dig deeper into what people really feel. Its more than just what they do and its far more than what they say. We measure the underlying subconscious nature of how people process information, emotion, and decisions. That pushes the boundaries for how science can become more usefully blended in with art.

Howard: I think thats a great way of articulating what Ive been writing about a lot lately. It's not science or creative, its that you're looking at two sides of the same coin and youve got to figure out how to make them hand-in-glove. I think that's what you were saying, right?

Gerrol: Yes, it absolutely is. Science and art need to work better together. That means that as much as ever, we need emotionally intelligent people to contribute creative ideas that are worth scientifically testing, but we also need new ways to measure beyond big data that lacks empathy, or self-report that fosters biases.

Step one is getting people to understand the true impact of emotion. While we think were rational beings, at the end of the day, our emotions and our instincts are driving us. Emotion is controlling all of our perceptions, decisions, and actions. When we realize that and see how important emotion is, we then recognize that we need to be able to measure it.

All of the old ways of evaluating impact are not giving us effective data to understand that emotional layer. To get there, neuroscience unlocks the ability to measure in a way that we couldn't have done before. We can actually measure emotion, do it with second-by-second precision, and quantify what was previously unquantifiable, confidently understanding the emotional impact of a given piece of creative.

Howard: The last decade of neuroscience left a lot to be desired. There seems to be a new frontier ahead of us. I'd love if you could articulate why this is happening and how much things have changed related to the efficacy of the field?

Gerrol: Neuroscience, for all intents and purposes, is a fledgling industry with the amount we know about the human brain still barely scratching the surface. In fact, every hard science, even things like physics, start out part philosophy. Remember, there was a time when we were trying to figure out whether or not the earth was flat or round or if the earth rotated around the sun, or vice versa. Great philosophers debated about these scientific questions because we didn't yet have all the measurement tools necessary. There was this mixing of philosophy and science that eventually gave way to more hard science.

Neuroscience has been in that same realm, mixing philosophy and science. First, we debated about emotion and decision-making (and we still debate about the nature of consciousness), but eventually our measurement tools evolved.

It also goes far beyond the tools themselves. EEG, for example, is a device that measures brain activity and has been around for nearly one hundred years. However, it is also a tool that collects massive amounts of often messy data that is hard to make sense of, far more than even the most brilliant scientist can manage manually.

With EEG you are looking at the brain releasing electricity through your scalp, at very small amounts, in different locations, with different frequencies, and different amplitudes of electricity. Meanwhile, every time somebody blinks, clenches their jaw, or any muscle movement or electrical interference creates noise in the data. Now computational power is leagues beyond what it was even just a few years ago and data science has allowed us to leapfrog what was possible before.

In our new world, we have the ability to clean out those noisy artifacts, train algorithms using a data-driven process through machine learning, and do so real-time as the data is being collectedno more waiting weeks for data processing. We quite literally process emotional reactions live as they are coming straight from your brain.

Howard: These advances are so exciting and its amazing to see how far practical applications of neuroscience have come. With all of these advances, what should we be careful of?

Gerrol: Yes, the science has come a long way, but buyer beware. There are still, perhaps more than ever, people peddling snake oil. I sometimes compare it to buying a bottle of wine as someone like me who is not a wine connoisseur. When I go to buy a bottle of wine, I look at the label, I look at the price and I think, OK. this one's a little more expensive than that one and the label looks nice, so I'll buy it. But, I don't really know if its a good bottle as I'm not a wine expert. Similarly, because neuroscience is such a complex topic, people should be skeptical and be able to come at any of us in this industry and ask the hard questions.

If you smell B.S. its likely you might be onto something. Your emotions, as usual, are probably telling you something valuable. We need to continue to be aware of that, because much like I'm not a wine connoisseur, your customer is likely not a neuroscientist. We need to make sure that we hold the industry to a high standard.

Howard: All terrific points. Thanks for so clearly explaining all of that. Last question. I think of you as an artist of science and Id love to hear your thoughts on what the relationship between creatives and scientists needs to look like as we move forward.

Gerrol: Thank you Billee. I appreciate that and am looking forward to our future collaboration together through that lens.

If you look at how research and creative have evolved, its different across different industries. I've been a part of the user experience industry for over 15 years, then the advertising industry, and the entertainment world, which are all totally different animals when it comes to research. If you talk about research to support designing a better website or app, you don't get much pushback on using data to help drive the decisions. Because web design and app design grew up within a data-driven age, it's less of a confrontational relationship and more of a symbiotic relationship.

With advertising, on the other hand, and even more so in Hollywood, there can be tension between research and creative. Advertising didn't grow up with science as part of the process. Science came later and the type of science being used is typically rooted in self-reported opinions. Think of the old Henry Ford adage, If I had asked people what they wanted, they would have said faster horses.

Artists naturally dont want the opinions of every person in the focus group to be treated like their creative director. In fact, all of that feedback can create an aversion to risk and water down the art. So the industry produces too much of the same and not enough stands out.

This has led to a new opportunity in todays world where relationship creatives and scientists can once again be symbiotic. We, as scientists, should respect and admire the emotional instincts that create great art. Instead of stepping on toes with peoples rationalized opinions, we can now provide a measurement that hits at the heart of what creatives really care aboutare people emotionally engaged?

This allows us to empower creatives with data that they can make actionable. We have reached a point where neuroscience can be the tool that creatives lean on to find opportunities to confidently try new things, take risks, and reinforce great storytelling instead of watering down the art.

Read more:
Brand Alchemy: A Conversation With Artist Of Science Spark Neuros Spencer Gerrol - Forbes

These Breakthroughs Made the 2010s the Decade of the Brain – Qrius

I rarely use the words transformative or breakthrough for neuroscience findings. The brain is complex, noisy, chaotic, and often unpredictable. One intriguing result under one condition may soon fail for a majority of others. Whats more, paradigm-shifting research trends often require revolutionary tools. When were lucky, those come once a decade.

But I can unabashedly say that the 2010s saw a boom in neuroscience breakthroughs that transformed the field and will resonate long into the upcoming decade.

In 2010, the idea that wed be able to read minds, help paralyzed people walk again, incept memories, or have multi-layered brain atlases was near incomprehensible. Few predicted that deep learning, an AI model loosely inspired by neural processing in the brain, would gain prominence and feed back into decoding the brain. Around 2011, I asked a now-prominent AI researcher if we could automatically detect dying neurons in a microscope image using deep neural nets; we couldnt get it to work. Today, AI is readily helping read, write, and map the brain.

As we cross into the next decade, it pays to reflect on the paradigm shifts that made the 2010s the decade of the brain. Even as a boo humbug skeptic Im optimistic about the next decade for solving the brains mysteries: from genetics and epigenetics to chemical and electrical communications, networks, and cognition, well only get better at understanding and tactfully controlling the supercomputer inside our heads.

Weve covered brain-computer interfaces (BCIs) so many times even my eyes start glazing over. Yet I still remember my jaw dropping as I watcheda paralyzed man kick off the 2014 World Cupin a bulky mind-controlled exosuit straight out ofEdge of Tomorrow.

Flash forward a few years, and scientists have already ditched the exosuit for an implanted neural prosthesis that replaces severed nerves to re-establish communication between the brains motor centers and lower limbs.

The rise in BCIs owes much tothe BrainGate project, which worked tirelessly to decode movement from electrical signals in the motor cortex, allowingparalyzed patients to use a tablet with their mindsoroperate robotic limbs. Today, prosthetic limbs coated with sensors can feed back into the brain, giving patients mind-controlled movement, sense of touch, and an awareness of where the limb is in space. Similarly, by decoding electrical signals in the auditory or visual cortex, neural implants can synthesize a persons speech by reconstructing what theyre hearing or re-create images of what theyre seeingor even of what theyre dreaming.

For now, most BCIsespecially those that require surgical implantsare mainly used to give speech or movement back to those with disabilities or decode visual signals. The brain regions that support all these functions are on the surface, making them relatively more accessible and easier to decode.

But theres plenty of interest in using the same technology to target less tangible brain issues, such as depression, OCD, addiction, andother psychiatric disordersthat stem from circuits deep within the brain. Several trials using implanted electrodes, for example, have shown dramatic improvement in peoplesuffering from depressionthat dont respond to pharmaceutical drugs, but the results vary significantly between individuals.

The next decade may see non-invasive ways to manipulate brain activity, such as focused ultrasound, transcranial magnetic or direct current stimulation (TMS/tDCS), and variants of optogenetics. Along with increased understanding of brain networks and dynamics, we may be able to play select neural networks like a piano and realize the dream of treating psychiatric disorders at their root.

Rarely does one biological research field get such tremendous support from multiple governments. Yet the 2010s saw an explosion in government-backed neuroscience initiatives from theUS,EU,and Japan, with China, South Korea, Canada, and Australia in the process of finalizing their plans. These multi-year, multi-million-dollar projects focus on developing new tools to suss out the brains inner workings, such as how it learns, how it controls behavior, and how it goes wrong. For some, the final goal is to simulate a working human brain inside a supercomputer, forming an invaluable model for researchers to test out their hypothesesand maybe act as a blueprint for one day reconstructing all of a persons neural connections, called the connectome.

Even as initial announcementsweremet with skepticismwhat exactly is the project trying to achieve?the projects allowed something previously unthinkable. The infusion of funding provided a safety blanket to develop new microscopy tools to ever-more-rapidly map the brain, resulting in a toolkit of new fluorescent indicators that track neural activation and map neural circuits. Even rudimentary simulations have generated virtual epilepsy patients to help more precisely pinpoint sources of seizures. A visual prosthesis to restore sight,a memory prosthesisto help those with faltering recall, anda push for non-invasive waysto manipulate human brains all stemmed from these megaprojects.

Non-profit institutions such as the Allen Institute for Brain Science have also joined the effort, producingmap after mapat different resolutions of various animal brains. The upcoming years will see individual brain maps pieced together into comprehensive atlases that cover everything from genetics to cognition, transforming our understanding of brain function from paper-based 2D maps into multi-layered Google Maps.

In a way, these national programs ushered in the golden age of brain science, bringing talent from other disciplinesengineers, statisticians, physicists, computer scientistsinto neuroscience. Early successes will likely drive even more investment in the next decade, especially as findings begin translating into actual therapies for people who dont respond to traditional mind-targeting drugs. The next decade will likely see innovative new tools that manipulate neural activity more precisely and less-invasively than optogenetics. The rapid rise in the amount of data will also mean that neuroscientists will quickly embrace cloud-storage options for collaborative research and GPUs and more powerful computing cores to process the data.

First, brain to AI. The physical structure and information flow in the cortex inspired deep learning, the most prominent AI model today. Ideas such as hippocampal replaythe brains memory center replays critical events in fast forward during sleep to help consolidate memoryalso benefit AI models.

In addition, the activation patterns of individual neurons merged with materials science to build neuromorphic chips, or processors thatfunction more like the brain, rather than todays silicon-based chips. Althoughneuromorphic chipsremain mainly an academic curiosity, theyhave the potentialto perform complicated, parallel computations at a fraction of the energy used by processors today. As deep neural nets get ever-more power hungry, neuromorphic chips may present a welcome alternative.

In return, AI algorithms that closely model the brain are helping solve long-time mysteries of the brain, such ashow the visual cortex processes input. In a way, the complexity and unpredictability of neurobiology is shriveling thanks to these computational advancements.

Although crossovers between biomedical research and digital software have long existedthink programs that help with drug designthe match between neuroscience and AI isfar stronger and more intimate. As AI becomes more powerful and neuroscientists collaborate outside their field, computational tools will only unveil more intricacies of neural processing, including more intangible aspects such as memory, decision-making, or emotions.

I talk a bunch about the brains electrical activity, but supporting that activity are genes and proteins. Neurons also arent a uniform bunch; multiple research groups are piecing together a whos who of the brains neural parts and their individual characteristics.

Although invented in the late 2000s, technologies such as optogenetics and single-cell RNA sequencing were widely adopted by the neuroscience community in the 2010s. Optogenetics allows researchers to control neurons with light, even in freely moving animals going about their lives. Add to that a whole list of rainbow-colored proteins to tag active cells, and its possible to implant memories. Single-cell RNA sequencing is the queen bee of deciphering a cells identity, allowing scientists to understand the geneticexpressionprofile of any given neuron. This tech is instrumental in figuring out the neuron populations that make up a brain at any point in timeinfancy, youth, aging.

But perhaps the crown in new tools goes to brain organoids, or mini-brains, that remarkably resemble those of preterm babies, making them excellent models of the developing brain. Organoids may be our best chance of figuring out the neurobiology of autism, schizophrenia, and other developmental brain issues that are difficult to model with mice. This decade is when scientists established a cookbook for organoids of different types; the next will see far more studies that tap into their potential for modeling a growing brain. With hard work and luck, we may finally be able to tease out the root causes of these developmental issues.

Shelly Xuelai Fan is a neuroscientist-turned-science writer. She completed her PhD in neuroscience at the University of British Columbia, where she developed novel treatments for neurodegeneration. While studying biological brains, she became fascinated with AI and all things biotech. Following graduation, she moved to UCSF to study blood-based factors that rejuvenate aged brains. She is the co-founder of Vantastic Media, a media venture that explores science stories through text and video, and runs the award-winning blog NeuroFantastic.com. Her first book, Will AI Replace Us? (Thames & Hudson) will be out April 2019.

This article was originally published in Singularity Hub

Stay updated with all the insights.Navigate news, 1 email day.Subscribe to Qrius

Read the original post:
These Breakthroughs Made the 2010s the Decade of the Brain - Qrius

The changing nature of approvals what does the future hold? – PMLiVE

We will continue to see geographic and therapeutic rebalancing. Growth in sales volume is slowing in the US and Europe, while greater activity has been observed in Mainland China. Regulatory processes in Mainland China have become more streamlined, resulting in greater investment by global pharma companies and more approvals of innovative medicines. Therapeutically, oncology and rare diseases will likely remain attractive candidates for investment, while market failures for neuroscience and anti-infective therapies will continue to negatively affect investment in those areas.

Digital technologies and artificial intelligence are creating new opportunities to identify new targets, leverage real-world data, rapidly test hypotheses and support clinical decision-making. Along with this, however, comes new challenges such as integrating the data sources needed to support robust machine learning. Therefore, the industry needs to develop solutions that provide a single source of truth to inform the decision-making process.

Finally, 2019 is tracking to be on par with 2012 and 2017 for the highest number of CEO changes within pharma companies and has the second highest number of changes within thetop 12 pharma companies. With these significant leadership changes, we should expect to continue to see additional changes within the industry for at least the next few years.

The analysis from CMR International highlights important questions about the sustainability of the pharmaceutical industry and provides objective insights that can inform discussions about how to move forward. It will be important to use ever-more sophisticated data sets to continue to understand pharmas ongoing evolution.

Read more from the original source:
The changing nature of approvals what does the future hold? - PMLiVE

Should Fertility Patients Be Given What They Want, or What They Need? – BioNews

20 January 2020

The final session of the Progress Educational Trust (PET)'s annual conference 'Reality Check: A Realistic Look at Assisted Reproduction' asked: 'Should Fertility Patients Be Given What They Want, or What They Need?'

Sally Cheshire, Chair of the Human Fertilisation and Embryology Authority (HFEA), said that what fertility patients want most of all is a baby, or at least the chance to have a baby. She explained that many patients will do anything to achieve their aim, and that the regulator's job is to help them achieve this in the best way possible, as part of good care. She went on to explain that many patients won't (at least initially) get what they want, raising the point that 60 percent of patients self-fund their treatment, so the HFEA must help ensure that all patients get what they need.

As part of what patients need, Cheshire spoke about the information available to patients and the fact that honest, unbiased opinion about what might work needs to be published and transparent. She explained that it is difficult to regulate new and emerging treatments (not least the 'add-ons' discussed in earlier conference sessions), and that many of these treatments are not, in fact, currently regulated by the HFEA. However, the HFEA can offer information allowing patients to make informed choices about potential treatments, especially when it is sometimes hard for patients to find uncontradictory and unbiased information for themselves.

Overall, Cheshire's message was that the HFEA does not support patients spending money on (often unnecessary) 'add-on' treatments, citing an HFEA survey from last year, showing that three-quarters of patients had at least one add-on with their treatment. The HFEA rates 11 add-ons using a traffic light system. The green rating is reserved for procedures or techniques that have been shown to be effective and safe by at least one good-quality, randomised clinical trial. It was reported in the survey that none of the most common add-ons used were rated green.

Cheshire argued that clinicians selling add-ons without evidence do the fertility sector, and patients, a disservice. The HFEA will continue, as part of the inspections process, to look at information available on clinics' websites and at claims made by these clinics, as well as keeping an eye on some advice coming from the non-regulated sector.

In the next presentation, Dr Jane Stewart, chair of the British Fertility Society (BFS), asked what was difficult about taking medical advice. She said that the role of 'Dr Google' and events like the Fertility Show has both good and bad aspects. It is good that there is much up-to-date information available that can usefully stimulate debate, but this is mixed with out-of-date and commercially influenced information. How might patients tell the difference?

Dr Stewart went on to explain how the doctor-patient relationship has evolved over time, towards a spirit of mutual co-operation and patient-centred care, describing the doctor as a 'bridge between the world of medicine and the expectations and needs of patients'. She pondered whether reproductive medicine had redefined patients as consumers (she insisted on using the word 'patient') and asked what the harm is in giving all patients what they want. The harm, she said, can come from the fact that many patients are vulnerable, some are ill-informed, and most will do anything (including pay) to have the chance of having a child. Thus, the doctor has a duty to help the patient come to the right decisions for them, even if that means challenging their expectations and assumptions. 'It's OK to say no', she argued.

Professor Bobbie Farsides then told us about the power of words, explaining that 'wants' are something that we feel we would like to have, do or be. Simply, a preference. By contrast, 'needs' are things we require, because they are essential or important, not just desirable. She explained that it is easier to claim support for needs as they have more societal endorsement, whereas some wants are not seen as acceptable (though some individual assertions of needs are also deemed unacceptable). 'What starts as a dream becomes a project that's all-consuming', she said, adding 'for example the desire to become a mother turns into a need'.

Structural issues shape expectations in this domain, including the way society thinks and talks about parenthood and about what women are expected to do. Professor Farsides said that given these significant pressures, we (including the fertility sector) must ask whether there is a particular form of vulnerability in patients wanting what others want them to want. She argued that professionals must present a 'fair offer', for patients to consider and maybe accept, that is not against the patients' interests.

PET's head of communications Dr Catherine Hill then gave a personal response to the wants-versus-needs question, telling her story of infertility and the phone call, when she was 21, that changed the course of her life. What she wanted was a large family, though what she needed after that call was help and support, but she was offered none. She described this time as traumatic, leaving her needing to try to forge a new identity as a potential fertility patient.

On starting fertility treatment at 37years of age, she was shocked to find that she was not eligible forIVF on the NHS, but pleased to be told she 'had the eggs of a 30-year old'. This turned out not to be true the test she was given only measured quantity, not quality. A new clinic told her to use an egg donor, and, when she used her own eggs, the clinicsuggested preimplantation genetic screening (PGS) (itself a contentious 'add-on'). This resulted in two embryos, and led to her having a daughter.

Dr Hill said she wished she had been better informed throughout this process. She argued that fertility patients' needs include emotional support, fair access to NHS-funded IVF, fertility education (which becomes more pressing as more and more procedures are offered), and better fertility preservation options. She added that funding of NHS fertility services, as well as monitoring of the funding situation, is incredibly important.

In the discussion chaired by Fiona Fox, chief executive of the Science Media Centre, there was generally much agreement with the speakers. Cheshire, responding to a point from the audience, said that fertility education was not a key responsibility of the HFEA but that they try to do it anyway. She added that the BFS has an ongoing education project, and suggested that perhaps the HFEA could be a conduit for information in new ways in future. Dr Hill added that it was hard to fathom why fertility educationand the Fertility Fairness campaign lacks funding, when the fertility industry is worth so much.

Professor Farsides said that the old-fashioned view that the regulator was something to push against no longer holds true. She argued that clinics, and the fertility industry more widely, should work with the regulator to ensure that patients get both what they want and what they need.

The Progress Educational Trust (PET) would like to thank the sponsors of its conference - the Anne McLaren Memorial Trust Fund, Edwards and Steptoe Research Trust Fund, CooperSurgical, the European Sperm Bank, Ferring Pharmaceuticals, the London Women's Clinic, NGA Law and the Institute of Medical Ethics.

PET's next public events will be:

See original here:
Should Fertility Patients Be Given What They Want, or What They Need? - BioNews

Amy Hart tells Loose Women she will be freezing her eggs due to early menopause concerns – Worthing Herald

Former Love Island contestant Amy Hart from Worthing said she will be freezing her eggs due to fears she may be facing early menopause.

The 27-year-old appeared on Loose Women this afternoon (January 17) to raise awareness about her situation, which many women in the UK face, and the fertility options open to them as part of the show's fertility week.

Amy said she recently went for a fertility 'MOT', in which the doctor did an internal scan of her ovaries and a blood test to check her Anti-Mllerian hormone, or AMH, levels. While her ovaries were normal, her hormone levels came back at 8.5 - with 20 being the optimum level.

Read more:

Love Island: Amy Hart cheers on fellow Worthing contestant Connor Durman

As her mother Sue went through the menopause aged 44, and her grandmother and aunt at 42 - all classified as early menopause by the NHS - Amy decided she will have her eggs frozen in the coming months, despite saying she had never had any problems with her periods.

She said the intensive treatment involved ten days of injections 'to make your hormones go into overdrive' and being put under general anaesthetic for them to be harvested.

She said: "I did always think I could do whatever I want, my 20s are for me and my 30s are for having kids. Lovely. And then you go, 'oh actually, that isn't my decision, that is my body's decision'.

"I would love to meet someone, get married, have kids naturally, fine. That is my dream idea. But if that doesn't happen, I have got my insurance policy."

According to the Human Fertilisation and Embryology Authority, the whole process for egg freezing and thawing costs an average of 7,000 to 8,000, and it has a fairly low level of success; in 2017, 19 per cent of IVF treatments using a patients own frozen eggs resulted in a baby being born.

Loose Women anchor Kaye Adams questioned Amy's decision. She said: "The NHS doesn't provide this service and they don't particularly recommend it. Look: you are 27, maybe you just need to chill out and let things go a little bit."

But fellow panellist Stacey Solomon, who also had a family history of early menopause, supported Amy's decision. She said she had considered having the treatment herself, and that there was an argument that the NHS should provide egg freezing treatments to women with a proven family history of early menopause.

According to the NHS website, early menopause happens when a woman's periods stop before the age of 45.

If you are experiencing symptoms of the menopause, such as hot flushes or night sweats, it recommended seeing a GP. For further advice, click here.

Link:
Amy Hart tells Loose Women she will be freezing her eggs due to early menopause concerns - Worthing Herald

Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN – Dove Medical Press

Hossein Derakhshankhah, 1, 2,* Samira Jafari, 1, 2,* Sajad Sarvari, 3 Ebrahim Barzegari, 4 Faezeh Moakedi, 5 Milad Ghorbani, 6 Behrang Shiri Varnamkhasti, 1 Mehdi Jaymand, 7 Zhila Izadi, 1, 8 Lobat Tayebi 9

1Pharmaceutical Sciences Research Center, Health Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 2Zistmavad Pharmed Co., Tehran, Iran; 3Department of Pharmaceutical and Pharmacological Science, School of Medicine, West Virginia University, Morgantown, WV, USA; 4Medical Biology Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 5Department of Biochemistry and Molecular Biology, School of Medicine, West Virginia University, Morgantown, WV, USA; 6Department of Chemical Engineering, College of Engineering, University of Tehran, Tehran, Iran; 7Nano Drug Delivery Research Center, Health Technology Institute, Kermanshah University of Medical Sciences, Kermanshah, Iran; 8Department of Regenerative Medicine, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran; 9Marquette University School of Dentistry, Milwaukee, WI 53201, USA

*These authors contributed equally to this work

Correspondence: Zhila Izadi; Lobat Tayebi Email izadi_zh@razi.tums.ac.ir; lobat.tayebi@marquette.edu

Abstract: The advent of porous materials, in particular zeolitic nanoparticles, has opened up unprecedented putative research avenues in nanomedicine. Zeolites with intracrystal mesopores are low framework density aluminosilicates possessing a regular porous structure along with intricate channels. Their unique physiochemical as well as physiological parameters necessitate a comprehensive overview on their classifications, fabrication platforms, cellular/macromolecular interactions, and eventually their prospective biomedical applications through illustrating the challenges and opportunities in different integrative medical and pharmaceutical fields. More particularly, an update on recent advances in zeolite-accommodated drug delivery and the prevalent challenges regarding these molecular sieves is to be presented. In conclusion, strategies to accelerate the translation of these porous materials from bench to bedside along with common overlooked physiological and pharmacological factors of zeolite nanoparticles are discussed and debated. Furthermore, for zeolite nanoparticles, it is a matter of crucial importance, in terms of biosafety and nanotoxicology, to appreciate the zeolite-bio interface once the zeolite nanoparticles are exposed to the bio-macromolecules in biological media. We specifically shed light on interactions of zeolite nanoparticles with fibrinogen and amyloid beta which had been comprehensively investigated in our recent reports. Given the significance of zeolite nanoparticles interactions with serum or interstitial proteins conferring them new biological identity, the preliminary approaches for deeper understanding of administration, distribution, metabolism and excretion of zeolite nanoparticles are elucidated.

Keywords: zeolite, mesoporous, nanostructure, biosafety, biomedical applications

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

More here:
Biomedical Applications of Zeolitic Nanoparticles, with an Emphasis on | IJN - Dove Medical Press

A Protein At the Center of Cell Division: Researchers Discover the Wonders TPX2 Can Do During Cell Division – Science Times

(Photo : Natanel Mansilla on Flickr)

Cell division is a relatively familiar concept for everyone since it is one of the recurring topics in biology -- mitosis and meiosis, and all.Cell division is importantfor the reproduction, and repair of the tissues and over-all growth of the organism. However, rapid cell division leads to the formation of tumors which, most of than not,leads to cancer. Recently, a team of researchers from Princeton University successfully recreated an important process in cell division in a test tube. This experiment helped them uncover the vital role of a protein that is elevated in over 25% of all cancers.

The findings, which arepublished in Nature Communications, describes a key step towards the recreation of the entire cell division machinery that can lead to new therapies with the primary goal of preventing the growth of cancer cells. Usually, when cells undergo division, themicrotubules (those spindle-shaped structures composed of thousand of filaments)attaches itself to the chromosomes then pulls each chromosome into each newly-forming cell. Each of these microtubules is assembled from tubulin molecules and because the chromosomes must assemble intro these microtubules at the right moment, an error in segregation can lead to cancer. To be able to complete this process correctly, another process called branching microtubule nucleation is necessary. The branching microtubule nucleation is crucial because it allows the cells to form a huge amount of microtubules enabling the capture of the chromosomes.

READ:Laser Can Detect Cancer Cells and Kill It

The crucial process of the branching microtubule nucleation is depending largely on several pieces of "molecular machinery". For instance, the gamma-tubulin ring complex is the one responsible for initiating the assembly of tubulin molecules into microtubules. Meanwhile, theaugmin complexis the one responsible for engaging the gamma-tubulin ring complex to the existing microtubules. The Targeting Protein for Xklp2 or TPX2 is also involved in this process, however, researchers identified that this is protein is elevated in over 25% in all forms of cancer.

The elevated TPX2 levels can lead to the abnormal assembly of microtubules in cells. Sabine Petry, an assistant professor of molecular biology, explains that to be able to better understand branching microtubule nucleation, the researchers had to do the process outside of the cell using putrified proteins. The researchers found out thatlike the augmin complex, TPX2 can bind microtubules and recruit gamma-tubulin ring complexto initiate the process of branching microtubule nucleation. They were also surprised to discover that TPX2 is also responsible for recruiting augmin to microtubules.

According to graduate student Raymundo Alfaro-Aco, the process of branching microtubule nucleation occurs most efficiently when the three molecular pieces are all present. "Surprisingly, TPX2 is at the heart of controlling this process even though it is a single protein." He said. In the published paper, Petry and her graduate student Matthew King further explains that TPX2 forms a liquid layer on the surface of existing microtubules to promote branching microtubule nucleation. These liquid layers will bead up into droplets containing tubulin. The team was also able to discover that TPX2 and tubulin can condense together to form droplets through a phase-separation mechanism (kind of similar to the mechanism that makes oil droplets form in water).

A new batch of microtubules can be formed from these droplets and can result in the formation of branched microtubule structures by condensing on the surface of the existing microtubules. King explains that the condensation of TPX2 and tubulin creates a reservoir of tubulin in a pre-existing microtubule. "It may be necessary to efficiently promote the process of branching microtubule nucleation." He said.

View post:
A Protein At the Center of Cell Division: Researchers Discover the Wonders TPX2 Can Do During Cell Division - Science Times

The biology of coffee, the world’s most popular drink – The Conversation AU

Youre reading this with a cup of coffee in your hand, arent you? Coffee is the most popular drink in the world. Americans drink more coffee than soda, juice and tea combined.

How popular is coffee? When news first broke that Prince Harry and Meghan were considering Canada as their new home, Canadian coffee giant Tim Hortons offered free coffee for life as an extra enticement.

Given coffees popularity, its surprising how much confusion surrounds how this hot, dark, nectar of the gods affects our biology.

The main biologically active ingredients in coffee are caffeine (a stimulant) and a suite of antioxidants. What do we know about how caffeine and antioxidants affect our bodies? The fundamentals are pretty simple, but the devil is in the details and the speculation around how coffee could either help or harm us runs a bit wild.

The stimulant properties of caffeine mean that you can count on a cup of coffee to wake you up. In fact, coffee, or at least the caffeine it contains, is the most commonly used psychoactive drug in the world. It seems to work as a stimulant, at least in part, by blocking adenosine, which promotes sleep, from binding to its receptor.

Caffeine and adenosine have similar ring structures. Caffeine acts as a molecular mimic, filling and blocking the adenosine receptor, preventing the bodys natural ability to be able a rest when its tired.

This blocking is also the reason why too much coffee can leave you feeling jittery or sleepless. You can only postpone fatigue for so long before the bodys regulatory systems begin to fail, leading to simple things like the jitters, but also more serious effects like anxiety or insomnia. Complications may be common; a possible link between coffee drinking and insomnia was identified more than 100 years ago.

Different people respond to caffeine differently. At least some of this variation is from having different forms of that adenosine receptor, the molecule that caffeine binds to and blocks. There are likely other sites of genetic variation as well.

There are individuals who dont process caffeine and to whom drinks like coffee could pose medical danger. Even away from those extremes, however, there is variation in how we respond to that cup of coffee. And, like much of biology, that variation is a function of environment, our past coffee consumption, genetics and, honestly, just random chance.

We may be interested in coffee because of the oh-so-joyous caffeine buzz, but that doesnt mean that caffeine is the most biologically interesting aspect of a good cup of coffee.

In one study using rats, caffeine triggered smooth muscle contraction, so it is possible that caffeine directly promotes bowel activity. Other studies, though, have shown that decaffeinated coffee can have as strong an effect on bowel activity as regular coffee, suggesting a more complex mechanism involving some of the other molecules in coffee.

What about the antioxidants in coffee and the buzz that surrounds them? Things actually start out pretty straightforward. Metabolic processes produce the energy necessary for life, but they also create waste, often in the form of oxidized molecules that can be harmful in themselves or in damaging other molecules.

Antioxidants are a broad group of molecules that can scrub up dangerous waste; all organisms produce antioxidants as part of their metabolic balance. It is unclear if supplementing our diet with additional antioxidants can augment these natural defences, but that hasnt stopped speculation.

Antioxidants have been linked to almost everything, including premature ejaculation.

Are any of the claims of positive effects substantiated? Surprisingly, the answer is again a resounding maybe.

Coffee wont cure cancer, but it may help to prevent it and possibly other diseases as well. Part of answering the question of coffees connection to cancer lies in asking another: what is cancer? At its simplest, cancer is uncontrolled cell growth, which is fundamentally about regulating when genes are, or are not, actively expressed.

My research group studies gene regulation and I can tell you that even a good cup of coffee, or boost of caffeine, wont cause genes that are turned off or on at the wrong time to suddenly start playing by the rules.

The antioxidants in coffee may actually have a cancer-fighting effect. Remember that antioxidants fight cellular damage. One type of damage that they may help reduce is mutations to DNA, and cancer is caused by mutations that lead to the misregulation of genes.

Studies have shown that consuming coffee fights cancer in rats. Other studies in humans have shown that coffee consumption is associated with lower rates of some cancers.

Interestingly, coffee consumption has also been linked to reduced rates of other diseases as well. Higher coffee consumption is linked to lower rates of Parkinsons disease and some other forms of dementia. Strikingly, at least one experimental study in mice and cell culture shows that protection is a function of a combination of caffeine and antioxidants in coffee.

Higher coffee consumption has also been linked to lower rates of Type 2 diabetes. Complexity, combined effects and variation between individuals seems to be the theme across all the diseases.

At the end of the day, where does all this leave us on the biology of coffee? Well, as I tell my students, its complicated. But as most reading this already know, coffee will definitely wake you up in the morning.

[ Deep knowledge, daily. Sign up for The Conversations newsletter. ]

See the rest here:
The biology of coffee, the world's most popular drink - The Conversation AU

Body Clock Biologists Find That Beauty Sleep Is Real Discovery May Unlock the Mysteries of Aging – SciTechDaily

Biologists from The University of Manchester have explained for the first time why having a good nights sleep really could prepare us for the rigors of the day ahead.

The study in mice and published in Nature Cell Biology, shows how the body clock mechanism boosts our ability to maintain our bodies when we are most active. And because we know the body clock is less precise as we age, the discovery, argues lead author Professor Karl Kadler, may one day help unlock some of the mysteries of aging.

The discovery throws fascinating light on the bodys extracellular matrix which provides structural and biochemical support to cells in the form of connective tissue such as bone, skin, tendon, and cartilage. Over half our body weight is matrix, and half of this is collagen and scientists have long understood it is fully formed by the time we reach the age of 17.

But now the researchers have discovered there are two types of fibrils the rope-like structures of collagen that are woven by the cells to form tissues.

Thicker fibrils measuring about 200 nanometers in diameter a million million times smaller than a pinhead are permanent and stay with us throughout our lives, unchanged from the age of 17.

Colorful video showing cross-sections of different collagen fibrils and the effect of the body clock on the fibrils.

But thinner fibrils measuring 50 nanometers, they find, are sacrificial, breaking as we subject the body to the rigors of the day but replenishing when we rest at night.

The collagen was observed by mass spectrometry and the mouse fibrils were observed using state of the art volumetric electron microscopy funded by the Wellcome Trust every 4 hours over 2 days.

When the body clock genes were knocked out in mice, the thin and thick fibrils were amalgamated randomly.

Collagen provides the body with structure and is our most abundant protein, ensuring the integrity, elasticity, and strength of the bodys connective tissue, said Professor Kadler.

Its intuitive to think our matrix should be worn down by wear and tear, but it isnt and now we know why: our body clock makes an element which is sacrificial and can be replenished, protecting the permanent parts of the matrix.

He added: So if you imagine the bricks in the walls of a room as the permanent part, the paint on the walls could be seen as the sacrificial part which needs to be replenished every so often. And just like you need to oil a car and keep its radiator topped up with water, these thin fibrils help maintain the bodys matrix.

Knowing this could have implications on understanding our biology at its most fundamental level. It might, for example, give us some deeper insight into how wounds heal, or how we age.

Reference: Circadian control of the secretory pathway maintains collagen homeostasis by Joan Chang, Richa Garva, Adam Pickard, Ching-Yan Chlo Yeung, Venkatesh Mallikarjun, Joe Swift, David F. Holmes, Ben Calverley, Yinhui Lu, Antony Adamson, Helena Raymond-Hayling, Oliver Jensen, Tom Shearer, Qing Jun Meng and Karl E. Kadler, 6 January 2020, Nature Cell Biology.DOI: 10.1038/s41556-019-0441-z

Read more:
Body Clock Biologists Find That Beauty Sleep Is Real Discovery May Unlock the Mysteries of Aging - SciTechDaily